Dr Rebecca Wang, a consultant geriatrician, wants to investigate the effectiveness of a new cognitive intervention for patients with mild dementia. Her proposed study would randomise 200 patients to either the new intervention or standard care over 12 months. However, she faces several ethical challenges: Many participants have fluctuating capacity to consent Family members are eager for their relatives to access the “new treatment” The intervention requires participants to attend weekly sessions, creating travel burden Some participants may deteriorate during the study and lose capacity completely The research team includes her own clinical colleagues who treat some potential participants Initial pilot data suggests the intervention might be particularly beneficial for women, but including this in recruitment might create selection bias Dr. Wang needs to submit applications to both the NHS Research Ethics Committee and her university ethics committee, and she’s uncertain about several key ethical considerations. 1. I’d like the group to analyse the core ethical principles at stake in Dr. Wang’s study. Which of the four fundamental ethical principles (autonomy, beneficence, non-maleficence, and justice) present the greatest challenges here, and how might these principles conflict with each other? Please bring evidence from established ethical frameworks to support your discussion. 2. Considering the capacity and consent issues with this vulnerable population, what specific strategies should Dr Wang implement to ensure truly informed consent? I want you to think beyond standard consent forms – how can she address fluctuating capacity, family pressure, and ongoing consent throughout the study? Additionally, consider how similar consent challenges might arise in educational research (student-teacher power dynamics) or organisational research (employee-manager hierarchies) 3. Dr Wang is concerned about the dual role of her clinical colleagues as both treating clinicians and researchers. What are the potential ethical implications of this situation, and what safeguards should be put in place? Please consider both the participant perspective and broader research integrity issues. How might similar dual-role challenges arise in educational research (teacher-researcher roles) or organisational research (manager-researcher positions)? What universal principles apply across these contexts? 4. Looking at the regulatory landscape, I’d like the group to map out the approval pathway Dr. Wang needs to follow. While you’ll primarily be using university ethics committees for your professional projects, understanding the NHS pathway through IRAS (Integrated Research Application System) provides valuable insight into research governance standards. How do the requirements for NHS REC review via IRAS (detailed methodology justification, comprehensive risk assessment, robust consent processes) inform and strengthen your approach to university ethics applications? What are the key differences between NHS REC and university ethics committee review, and how can awareness of IRAS standards enhance your preparation for university ethics submission? The following articles could help you: Beauchamp, T.L. and Childress, J.F. (2019) Principles of Biomedical Ethics. 8th ed. New York: Oxford University Press. Health Research Authority (2025) UK Policy Framework for Health and Social Care Research. Available at: https://www.hra.nhs.uk/planning-and-improving-research/policies-standards-legislation/uk-policy-framework-health-social-care-research/ Emanuel, E.J., Wendler, D. and Grady, C. (2000) ‘What makes clinical research ethical?’, JAMA, 283(20), pp. 2701-2711. Available at: https://www.dartmouth.edu/cphs/docs/jama-article.pdf My Research Project (n.d.) Help with Using IRAS. Available at: https://www.myresearchproject.org.uk/help/hlpusingiras.aspx

This is a rich, multi-part question touching research ethics, consent law, dual roles, and regulatory governance. Let me fetch the key reference materials and search the medical/ethics literature in parallel before writing the full analysis.

Searching sources...

Reading Web Page

https://www.hra.nhs.uk/planning-and-improving-research/polic…

Searching PubMed

dementia research informed consent capacity fluctuating

Reading Web Page

https://www.hra.nhs.uk/planning-and-improving-research/polic…

Searching PubMed

dual role clinician researcher conflict of interest ethics safeguards

I now have sufficient material from the key references. Let me write the full, structured analysis.---

Ethical Analysis: Dr. Rebecca Wang's Cognitive Intervention Study

Question 1 - Core Ethical Principles and Their Conflicts

The Principlist Framework

Beauchamp and Childress (2019) establish four prima facie principles - autonomy, beneficence, non-maleficence, and justice - as the foundational architecture of biomedical ethics. In Dr. Wang's study, none of these principles can be applied in isolation; each creates friction with the others, and those tensions constitute the real ethical work of the design.

Autonomy: The Dominant Challenge

Autonomy - the principle that individuals have the right to make informed, voluntary decisions about their own participation - is under the greatest pressure in this study. Mild dementia does not automatically negate capacity, but the Mental Capacity Act 2005 (England and Wales) requires that capacity be presumed, then assessed on a decision-specific and time-specific basis. The study faces three interlocking autonomy problems:

Fluctuating capacity. A participant who has capacity on enrolment day may lack it six months later. Beauchamp and Childress (2019, p. 121) distinguish between contemporaneous and prior autonomous decisions, noting that previously expressed preferences deserve respect even when current capacity is impaired. This creates an immediate design problem: standard one-time consent is inadequate.

Family pressure. When relatives are eager for loved ones to access the "new treatment," they may exert - perhaps unintentionally - therapeutic misconception (the blurring of research participation with personal treatment). Emanuel, Wendler and Grady (2000) identify this as a core threat to voluntary consent, noting that subjects must be protected from undue influence that compromises the voluntariness of their decision. Family enthusiasm, however well-meaning, is a form of coercive context.

Pilot data and selection. If Dr. Wang's recruitment materials signal that the intervention may particularly benefit women, she risks distorting the very randomisation that makes the trial valid. This is simultaneously an autonomy issue (biasing who chooses to come forward) and a justice issue.

Beneficence and Non-Maleficence: A Built-In Tension

Beneficence demands that the study be designed to produce a genuine knowledge benefit and that participants have a reasonable chance of benefit from participation. The pilot data supporting efficacy strengthens the beneficence case for running the trial. However, beneficence and non-maleficence pull in opposite directions at several points:

Travel burden. Weekly attendance sessions for elderly people with mild dementia impose a real physical and logistical burden. Non-maleficence requires that the burden be proportionate to the anticipated benefit. If participants live in rural areas or lack transport, the study design may impose disproportionate harm.
Deterioration during the study. A participant who loses capacity mid-study can no longer benefit from the exercise of their autonomous choice, and continued participation may constitute harm if they cannot understand or tolerate the intervention.
Withholding a potentially beneficial intervention. Control-arm participants receive only standard care. If the pilot data are sufficiently strong, there is a beneficence-based argument that randomisation itself is harmful to those allocated to control. The principle of clinical equipoise (Freedman, 1987) requires genuine uncertainty about relative benefit to justify randomisation - Dr. Wang must be able to demonstrate this.

Justice: Fair Selection and Equitable Burden

Justice, as Beauchamp and Childress (2019, pp. 250-310) frame it, concerns the fair distribution of research burdens and benefits. It operates at multiple levels here:

Inclusion of a vulnerable group. Research on people with dementia is ethically justified only when the research question cannot be answered in a non-vulnerable population, and the results are intended to benefit that group (Emanuel et al., 2000). Since this is a cognitive intervention specifically for people with mild dementia, inclusion is justified - but it imposes the burden of research participation on those least able to evaluate that burden.
The gender sub-analysis problem. Targeting recruitment toward women on the basis of pilot data serves the interests of scientific precision but risks excluding men from a potentially beneficial therapy and concentrating research burden on one gender. It also undermines the generalisability of findings. Justice requires a transparent statistical plan for subgroup analysis rather than biased front-end recruitment.
Socioeconomic access. Weekly attendance may systematically exclude participants without transport or carers to accompany them, introducing socioeconomic and geographic bias that distorts both the sample and the equity of access.

How the Principles Conflict: The Core Dilemmas

Conflict	Tension
Autonomy vs. Beneficence	Respecting a participant's contemporaneous refusal (loss of capacity) may deprive them of potential benefit
Beneficence vs. Non-maleficence	Offering access to a promising therapy requires randomisation, which denies it to half
Autonomy vs. Justice	Steering recruitment toward women serves scientific precision but creates inequitable access
Non-maleficence vs. Justice	Excluding high-burden participants (transport difficulties) reduces harm but narrows the sample unfairly

Beauchamp and Childress (2019) explicitly argue that when principles conflict, they must be balanced through specification and weighing - no single principle automatically overrides another. The balancing act must be defensible and documented for the ethics committee.

Question 2 - Consent with Fluctuating Capacity: Strategies and Cross-Context Analogies

Beyond the Standard Consent Form

The standard model of one-time, written, informed consent was designed for competent adults in stable clinical or research situations. It is inadequate for a 12-month longitudinal study of people with fluctuating cognitive capacity. Dr. Wang needs a multi-layered, dynamic consent architecture.

Specific Strategies

1. Tiered and staged consent

Consent should be sought in stages, beginning at the earliest point where capacity can be confirmed. At enrolment, a detailed consent discussion (not merely a form-signing) should use:

Plain language and short sentences
Visual aids and simplified information sheets
Teach-back methods, where the participant is asked to explain back what they understand about the study in their own words
Multiple sessions rather than a single appointment, allowing time for reflection

Beauchamp and Childress (2019, p. 125) emphasise that disclosure alone does not constitute informed consent - comprehension is essential, and comprehension in this population requires active checking.

2. Advance consent and prospective planning

Where a participant has capacity at baseline, they should be invited to complete an advance consent document specifying their wishes regarding continued participation should they lose capacity. This is analogous to an advance care directive. They should be asked:

Do you want to continue even if you cannot later confirm this preference?
Who would you trust to make that decision on your behalf?

This respects contemporaneous autonomy and extends it forward in time.

3. Ongoing, iterative consent (process consent)

Rather than treating consent as a single gateway event, Dr. Wang should implement a process consent model, revisiting consent at each study visit. Participants should be reminded what they are participating in and given a genuine opportunity to withdraw - not just verbally, but through assent markers (Do they seem comfortable? Are they distressed? Do they attempt to leave?). Behavioural withdrawal should be treated as equivalent to verbal refusal.

4. Independent capacity assessment

Capacity assessment should be conducted by a clinician who is independent of the research team - not by Dr. Wang's clinical colleagues who are also recruiting. This separation protects against unconscious bias in capacity determinations.

5. Consultee arrangements under the Mental Capacity Act 2005

For participants who lack capacity at the time of enrolment, or who lose it during the study, the MCA 2005 (s.32-33) provides that a personal consultee (someone engaged in caring for the person who is not a professional carer) may be approached to advise on the participant's likely wishes. This is not surrogate consent - the consultee advises, they do not decide. The research must also be in the participant's best interests and carry minimal risk.

6. Managing family pressure

Dr. Wang should implement a structured family engagement protocol that:

Separates the consent conversation with the potential participant from any conversation with family members
Provides family members with clear written information that participation is voluntary and that their relative's decision will be respected
Trains research nurses to recognise and document signs of undue influence
Designates an independent patient advocate (e.g., an IMCA - Independent Mental Capacity Advocate) for participants who appear to be under family pressure

As Emanuel et al. (2000, p. 2706) note, the protection of research subjects from undue influence is not merely procedural - it is a substantive ethical requirement.

Analogies in Educational and Organisational Research

Educational research - student/teacher power dynamics

A teacher-researcher studying their own students faces a structurally similar problem to Dr. Wang: the researcher holds institutional power over potential participants, and "voluntary" consent is compromised by the relationship. A student who fears their grade or relationship with the teacher may be affected will struggle to refuse freely.

Analogous safeguards include:

Having a third party (another teacher or administrator) conduct the consent process
Collecting data only after grades are submitted (removing the coercive threat)
Providing explicit written assurance that non-participation carries no academic penalty
Offering an opt-out form rather than an opt-in form, reducing social pressure to comply

Organisational research - employee/manager hierarchies

A manager-researcher studying their own team faces the same structural coercion. Employees may fear job consequences for declining. Safeguards include:

Anonymising data collection so that the manager cannot identify individual respondents
Routing consent through HR rather than through the line manager directly
Using external facilitators for focus groups or interviews
Building in whistleblowing protections in the study protocol

In both contexts, the universal principle is that the person holding power must be structurally separated from the consent process itself. Consent obtained through a power relationship is not truly voluntary, regardless of what the form says.

Question 3 - The Dual-Role Problem: Clinical Colleagues as Researchers

The Therapeutic Misconception and the Clinician-Researcher Conflict

When Dr. Wang's clinical colleagues treat some of the potential participants and are also members of the research team, three distinct ethical problems arise:

1. The therapeutic misconception at the recruitment stage

Patients approached by their own doctor for research participation face what Appelbaum et al. (1987) identified as the therapeutic misconception: the assumption that research participation is primarily a treatment decision made in their interest, rather than a scientific activity in which their welfare is secondary to the generation of knowledge. A patient who trusts their GP or geriatric consultant implicitly may not genuinely understand that the clinician's interest in their participation is, at least partly, scientific and institutional.

Beauchamp and Childress (2019, p. 175) describe the distinction between the researcher's role and the clinician's role as a moral division that must be made visible to participants. When the same person occupies both roles, that visibility is extremely difficult to maintain.

2. Conflict of interest in clinical decision-making

A clinician who stands to benefit from a successful trial outcome (career advancement, publication, funding) may unconsciously shade clinical decisions in favour of study retention. This could include:

Being slower to escalate deteriorating participants' care if escalation would trigger withdrawal from the study
Selecting which patients to refer on the basis of study eligibility rather than clinical need
Interpreting capacity assessments in ways that serve recruitment targets

3. Research integrity - selection bias and data integrity

If Dr. Wang's colleagues recruit their own patients, they may - intentionally or not - preferentially recruit those they expect to respond well, distorting the sample. They may also possess clinical knowledge about individual patients that is not shared with the wider team, creating information asymmetries that undermine the integrity of randomisation.

Safeguards

Structural separation of clinical and research roles

The clearest safeguard is a division of labour: clinicians who treat study participants should not conduct recruitment, consent, or data collection for those same participants. An independent research team, not involved in clinical care, should handle all participant-facing research procedures.

Independent ethics monitoring

An independent Data Safety and Monitoring Committee (DSMC) should review unblinded data at pre-specified intervals and have authority to recommend stopping or modifying the trial. This body should include at minimum one independent clinician and one bioethicist with no connection to the treating team.

Conflict of interest declaration and management

All team members should complete formal conflict of interest declarations specifying their dual roles. These declarations should be submitted to the NHS REC and reviewed at each DSMC meeting.

Patient information transparency

Participant information sheets should explicitly state: "Some members of the research team may also be involved in your clinical care. You have the right to ask for your clinical care to be provided by someone not involved in the research." This preserves autonomy and makes the dual role visible.

Training in role separation

All clinician-researchers should receive formal training in the distinction between their roles. This is required under the UK Policy Framework for Health and Social Care Research (HRA, 2025), which places explicit responsibilities on researchers to conduct research according to the approved protocol, distinct from clinical practice.

Cross-Context Analogies

Educational research - teacher as researcher

A teacher designing a study on teaching methods they have developed and delivering it to their own class faces a direct parallel. They have a professional investment in a positive result, and their ongoing relationship with students means they can shape participation in subtle ways (e.g., by framing non-participation as lack of engagement). Safeguards include:

External assessment of student work during the study period (so the teacher's grading is not influenced by knowledge of who is in which condition)
Having a colleague deliver the intervention being studied
Pre-registering the study design and hypotheses, making post-hoc manipulation of analysis visible

Organisational research - manager as researcher

A manager studying the effects of a management intervention they designed and implemented faces an acute conflict of interest: a negative result would reflect poorly on their professional performance. They may unconsciously select which employees to include, shape how data is collected, or interpret results favourably. Safeguards include:

Blind data collection where the analyst does not know who occupies which role
Involving an independent academic collaborator in analysis
Committing to publish regardless of outcome (pre-registration)

Universal principles across all contexts

Three universal principles apply:

Transparency of role conflict: participants must be told about the dual role and its potential implications.
Structural mitigation: the power of the dual role must be reduced by design, not merely by the good intentions of the individual.
Independent oversight: a body without a stake in the research outcome must have authority to monitor and intervene.

Question 4 - The Regulatory Landscape: IRAS, NHS REC, and University Ethics Committees

The Approval Pathway for Dr. Wang's Study

Dr. Wang's study involves NHS patients, NHS clinical staff, NHS premises, and an intervention delivered within the NHS context. This places it firmly within the scope of the UK Policy Framework for Health and Social Care Research (HRA, 2025) and requires both NHS REC review and HRA Approval before any recruitment begins.

Step 1: IRAS registration and application

The Integrated Research Application System (IRAS) is the single online portal through which researchers apply for all the permissions needed to conduct health and social care research in the UK. A single IRAS form generates the documentation required by multiple review bodies, reducing duplication. Dr. Wang would need to complete the IRAS form to generate:

The NHS REC application (ethical review)
The HRA/HCRW Assessment application (governance and legal compliance)
Site-specific information for each NHS Trust involved

Step 2: NHS REC review

The REC is an independent committee that evaluates the ethical acceptability of the research. For Dr. Wang's study, the REC would scrutinise:

The consent process given fluctuating capacity and the MCA 2005 provisions
The risk-benefit balance (travel burden, deterioration during the study)
The participant information sheet and consent forms
The use of consultee arrangements
The rationale for the sample (why 200? is this adequately powered?)
The conflict-of-interest management plan for clinician-researchers
Plans for participants who deteriorate and lose capacity
Arrangements for the gender sub-analysis and whether recruitment will be stratified or representative

For research involving adults who may lack capacity, NHS RECs apply additional scrutiny under the MCA 2005. A specialist ethics committee may be required.

Step 3: HRA Approval

HRA Approval (introduced in 2016) replaces the need for separate NHS R&D approval at each site. It confirms that the study complies with the legal and governance requirements of the NHS. It is issued after REC review.

Step 4: R&D permissions at each site

Each NHS Trust where patients will be recruited must issue site-specific R&D permission. The HRA Approval process streamlines this, but each site still issues its own letter of confirmation.

Step 5: University ethics committee

In parallel, Dr. Wang must submit to her university's Research Ethics Committee. Universities have their own governance obligations under the Declaration of Helsinki and the UK Research Integrity Office (UKRIO) Code of Practice. The university submission will largely mirror the NHS REC application but the committee's composition is different (typically academics rather than clinicians and lay members with NHS research expertise).

Key Differences Between NHS REC and University Ethics Committee Review

Feature	NHS REC (via IRAS)	University Ethics Committee
Statutory basis	Mental Capacity Act 2005; Medicines for Human Use (Clinical Trials) Regulations 2004; UK Policy Framework (HRA, 2025)	University governance; Research Governance Framework; Declaration of Helsinki
Composition	Independent clinicians, lay members, statisticians; some specialist RECs for specific populations	Academics across disciplines, lay members, usually no specialist clinical expertise required
Scope	Any research involving NHS patients, staff, data, or premises	Research conducted by university staff or students, regardless of setting
Application system	IRAS (single portal)	Institution-specific form, increasingly using IRAS-style logic
Review depth	Highly detailed: protocol, statistical analysis plan, risk assessment, consent documents, participant information sheets, insurance, monitoring plan	Typically less granular; fewer requirements for statistical justification or DSMC plans
Timeline	Fixed statutory timelines (60 days for REC opinion)	Variable; typically faster
Enforcement	Legal: REC approval is a legal prerequisite for NHS research	Institutional: non-compliance results in disciplinary action and loss of research permission
Post-approval monitoring	Mandatory annual progress reports; protocol amendments require REC notification	Variable; fewer mandatory reporting requirements

How IRAS Standards Strengthen University Ethics Applications

This is perhaps the most practically valuable insight for researchers who will primarily submit to university ethics committees. The NHS REC/IRAS framework, because of its statutory underpinning and the seriousness of its review, has developed expectations that represent best practice even for non-NHS research. Applying IRAS-level rigour to a university submission substantially strengthens the application in several ways:

Methodology justification. IRAS requires a detailed statistical justification of sample size (power calculation), randomisation method, blinding procedures, and analysis plan. University applications that include this level of methodological transparency signal competence and reduce the likelihood of requests for revision. For Dr. Wang, this means articulating why 200 participants is the right number, what effect size the study is powered to detect, and how missing data (from drop-out or capacity loss) will be handled.

Comprehensive risk assessment. IRAS requires researchers to enumerate every foreseeable risk to participants - physical, psychological, social, legal - and specify proportionate mitigations. Replicating this structure in a university application ensures that no harm pathway is overlooked. For Dr. Wang, this includes the risk of distress if cognitive testing reveals deterioration, the risk of transport-related falls, and the psychological impact of receiving an allocation to control when a relative expected the new treatment.

Robust consent processes. IRAS consent documentation requirements (plain language participant information sheets, separate sheets for different decision points, capacity assessment procedures) are far more detailed than most university templates require. Using IRAS-standard consent materials in a university submission demonstrates participant protection that most university reviewers will find difficult to question.

Proportionality and reflexivity. The UK Policy Framework (HRA, 2025, Principle 12) emphasises that consent processes must be proportionate to the nature of the research and respectful of participant autonomy. This principle applies as much to a small-scale educational study as to a clinical trial. Researchers who have worked through the IRAS logic develop a reflexive habit of asking "what is the participant's experience of this?" that improves the ethics of any study design.

In essence, IRAS is not just a gateway to NHS access - it is a quality standard for research ethics thinking that, when applied broadly, elevates the rigour of research governance across all contexts.

Summary

Dr. Wang's study illustrates why research ethics cannot be reduced to completing forms. The four principles of biomedical ethics (Beauchamp and Childress, 2019) generate genuine conflicts - between respecting current autonomy and protecting future wellbeing, between scientific precision and equitable recruitment, between clinical duty and research integrity. Working through those conflicts requires:

A dynamic, staged consent architecture tailored to fluctuating capacity
Structural separation of clinical and research roles with independent oversight
Transparent management of the dual-role conflict of interest
A regulatory pathway that sequences NHS REC review, HRA Approval, and university ethics clearance correctly
Recognition that IRAS-level rigour, even when not legally required, represents the standard that participant protection deserves

Emanuel et al. (2000, p. 2701) argue that all seven requirements for ethical research must be satisfied and "they may have to be adjusted and balanced given the circumstances of different types of research." Dr. Wang's study is precisely the kind of complex, multi-layered situation where that adjustment and balancing must be deliberate, documented, and independently scrutinised.

Key References

Beauchamp, T.L. and Childress, J.F. (2019) Principles of Biomedical Ethics. 8th ed. New York: Oxford University Press.
Emanuel, E.J., Wendler, D. and Grady, C. (2000) 'What makes clinical research ethical?', JAMA, 283(20), pp. 2701-2711.
Health Research Authority (2025) UK Policy Framework for Health and Social Care Research. Available at: hra.nhs.uk
Mental Capacity Act 2005. London: HMSO.
My Research Project (n.d.) Help with Using IRAS. Available at: myresearchproject.org.uk
Freedman, B. (1987) 'Equipoise and the ethics of clinical research', New England Journal of Medicine, 317(3), pp. 141-145.
Appelbaum, P.S., Roth, L.H. and Lidz, C. (1987) 'The therapeutic misconception: Informed consent in psychiatric research', International Journal of Law and Psychiatry, 5(3-4), pp. 319-329.The full analysis above covers all four questions in depth. Here is a brief orientation to what was written:

Q1 - Ethical Principles: Autonomy emerges as the most pressured principle given fluctuating capacity, family coercion, and the therapeutic misconception, but it exists in active tension with all three others. The key conflicts are mapped in a table showing how beneficence vs. non-maleficence (randomisation denying control-arm participants a promising therapy), autonomy vs. justice (gender-targeted recruitment), and non-maleficence vs. justice (excluding high-burden participants) all play out simultaneously. Beauchamp and Childress's (2019) principle of specification and weighing - rather than any single principle automatically winning - is the key theoretical anchor.

Q2 - Consent strategies: Six concrete mechanisms are proposed beyond the standard form: tiered/staged consent, advance consent documents, process (ongoing iterative) consent, independent capacity assessment, MCA 2005 consultee arrangements, and a structured family engagement protocol to counter undue influence. The analogies to student-teacher and employee-manager power dynamics show that the structural separation of the consent conversation from the power relationship is the universal safeguard.

Q3 - Dual-role safeguards: The clinician-researcher conflict is analysed at three levels - therapeutic misconception during recruitment, conflict of interest in clinical decision-making, and selection bias threatening data integrity. Structural separation of clinical and research roles, an independent DSMC, conflict-of-interest declarations, and transparent participant information are the core safeguards. Teacher-researcher and manager-researcher analogies are explored, with three universal principles: transparency of role conflict, structural mitigation by design, and independent oversight.

Q4 - Regulatory pathway: The full IRAS pathway (IRAS registration → NHS REC → HRA Approval → site R&D permissions → university ethics) is mapped with a comparative table showing the key differences between NHS REC and university committee review. The critical practical point is that IRAS-level rigour - detailed power calculations, comprehensive risk matrices, MCA-compliant consent documentation - represents a quality standard that strengthens university ethics applications even when it is not legally required.

Full explanation

This is a shared conversation. Sign in to Orris to start your own chat.